Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Testicular cancer.

M B Garnick1

  • 1Department of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Cambridge, Massachusetts.

Seminars in Surgical Oncology
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Testis cancer management is evolving, with surveillance for early stages and chemotherapy for advanced disease offering high cure rates. Research continues to improve outcomes for patients requiring salvage therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advanced prostate cancer: an update.

Reviews in urology·2006
Same author

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer.

Urology·2001
Same author

The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.

The Journal of urology·2001
Same author

Overview consensus statement. Fifth International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer.

Molecular urology·2001
Same author

Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group.

Molecular urology·2000
Same author

Comments on an in vitro model of hormonally refractory prostate cancer.

Cancer journal (Sudbury, Mass.)·2000
Same journal

Preoperative chemoradiation for locally advanced rectal cancer: rationale, technique, and results of treatment.

Seminars in surgical oncology·2003
Same journal

Preoperative chemoradiation for locally advanced rectal adenocarcinoma-the University of Florida experience.

Seminars in surgical oncology·2003
Same journal

Postoperative adjuvant therapy for pancreatic cancer.

Seminars in surgical oncology·2003
Same journal

Conformal chemoradiation for primary and metastatic liver malignancies.

Seminars in surgical oncology·2003
Same journal

Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer.

Seminars in surgical oncology·2003
Same journal

Combined modality therapy in esophageal cancer: the Memorial experience.

Seminars in surgical oncology·2003
See all related articles

Area of Science:

  • Oncology
  • Urology

Background:

  • Testis cancer management is dynamic, particularly for early-stage disease (Stage I and II).
  • The advent of curative chemotherapy has prompted a reevaluation of treatment strategies for all stages of germ cell tumors.

Purpose of the Study:

  • To review the fundamental aspects of testis cancer, including histology, clinical staging, and management approaches.
  • To provide an overview of current and evolving treatment paradigms for germ cell tumors of the testis.

Main Methods:

  • Review of current clinical protocols and management strategies for testis cancer.
  • Discussion of therapeutic options including orchiectomy, surveillance, retroperitoneal lymph node dissection, and chemotherapy.

Main Results:

Related Experiment Videos

  • Favorable prognostic features allow for orchiectomy followed by surveillance in early-stage testis cancer.
  • Metastatic disease has a favorable prognosis, with most patients cured by 9-12 weeks of combination chemotherapy.
  • Ongoing research focuses on salvage regimens and novel modalities like bone marrow transplantation for refractory cases.

    • Conclusions:

    • Current management strategies offer high cure rates for most testis cancer patients.
    • Continued research into novel therapies and prospective studies is crucial for improving outcomes in advanced and refractory germ cell tumors.
    • A comprehensive understanding of histology, staging, and management is essential for optimizing patient care.